Ipsen News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

03.06.15	Ipsen initiates a share buyback program (Businesswire)
03.06.15	Ipsen initiates a share buyback program (Businesswire)
02.06.15	Ipsen confirms its eligibility for PEA-PME (Businesswire)
02.06.15	Ipsen confirms its eligibility for PEA-PME (Businesswire)
29.05.15	Combined Shareholders’ Meeting of IPSEN S.A. held on 27 May 2015 (Businesswire)
07.05.15	Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
06.05.15	Ipsen : Combined Shareholders’ Meeting of 27 May 2015 (Businesswire)
05.05.15	Ipsen: Description of the Regulatory Framework of the Share Repurchase Program Proposed by the Board of Directors to the Approval of the Combined Shareholders’ Meeting to Be Held on 27 May 2015 (Businesswire)
29.04.15	Ipsen reports strong sales growth in Q1 2015 and raises guidance for the year (Businesswire)
16.04.15	Active Biotech and Ipsen Announce Their Decision to Discontinue the Development of tasquinimod in Prostate Cancer (Businesswire)
08.04.15	Ipsen : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
08.04.15	Ipsen and Hannover Medical School Start Joint Research in Recombinant Botulinum Neurotoxins for Targeted Secretion Inhibitors (Businesswire)
01.04.15	Ipsen Expands Ties to Harvard University with Signing of a New Research Alliance Agreement (Businesswire)
01.04.15	Ipsen inaugurates new Cambridge, MA R&D center, at the heart of the most important biomedical research & innovation hub in the USA, to expand U.S. presence (Businesswire)
31.03.15	The Ipsen Group Publishes Its 2014 Registration Document (Businesswire)
09.03.15	Ipsen : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
03.03.15	Ipsen’s 2014 Results and 2015 Financial Objectives (Businesswire)
02.03.15	Ipsen Announces Third Resupply of Increlex® (mecasermin [rDNA origin] Injection) in the U.S. in 2015 (Businesswire)
02.03.15	Dominique Laymand is Appointed as Ipsen’s Senior Vice President, Chief Ethics and Compliance Officer (Businesswire)
24.02.15	Ipsen Enters into Option Agreement to Acquire Canbex Therapeutics (Businesswire)
06.02.15	Ipsen : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
03.02.15	Ipsen: Sales in the Fourth Quarter and Full Year 2014 (Businesswire)
03.02.15	Ipsen announces topline results of two double-blind phase III studies of Dysport® in lower limb spasticity in children and in adults (Businesswire)
26.01.15	Ipsen announces topline results of two double-blind phase III studies of Dysport® in lower limb spasticity in children and in adults (Businesswire)
08.01.15	Half-Year IPSEN Liquidity Contract Statement Entered into with NATIXIS (Businesswire)
07.01.15	Ipsen : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
16.12.14	Ipsen’s Somatuline® Depot® is the First Therapy Approved by the FDA in the United States for the Treatment of Patients with Locally Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumors (Businesswire)
16.12.14	François Garnier Appointed Executive Vice President, General Counsel of Ipsen (Businesswire)
12.12.14	Ipsen Announces That the International Breast Cancer Study Group (IBCSG) Presented Phase 3 Results Evaluating the Use of Ovarian Suppression to Adjuvant Treatment with Tamoxifen (Businesswire)
09.12.14	Ipsen : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
28.11.14	Ipsen Announces FDA Acceptance of Filing for Dysport® in the Treatment of Upper Limb Spasticity in Adult Patients (Businesswire)
20.11.14	Ipsen and CNRS Create the "Archi-Pex" Joint Research and Innovation Lab, in Collaboration with the University of Rennes 1 and CEA (Businesswire)
12.11.14	Ipsen : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
06.11.14	Otonomy obtains rights to gacyclidine data from Ipsen to support development of OTO-311 as a treatment for tinnitus (Businesswire)
29.10.14	Ipsen: sales in the 3rd quarter and first nine months of 2014 (Businesswire)
22.10.14	Lexicon and Ipsen enter into ex-North America/Japan licensing and commercialization agreement for telotristat etiprate (Businesswire)
10.10.14	Ipsen Announces Positive Results from Phase III Clinical Study of Decapeptyl® (triptorelin pamoate) 11.25 mg Administered by Subcutaneous Route to Prostate Cancer Patients (Businesswire)
10.10.14	Aymeric Le Chatelier joins Ipsen as Executive Vice President, Chief Financial Officer (Businesswire)
07.10.14	Ipsen : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
02.10.14	Susheel Surpal Steps Down as Executive Vice President, Chief Financial Officer of Ipsen to Pursue Other Opportunities (Businesswire)
27.09.14	Ipsen Presents Preliminary Results of Exploratory Proof-of-Concept Study with Tasquinimod in Four Advanced Tumor Types at the ESMO 2014 Congress (Businesswire)
04.09.14	Ipsen : Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
01.09.14	Ipsen Announces Acceptance of Filings for Somatuline® in the Treatment of GEP-NET1s in the US with Priority Review and in Europe (Businesswire)
29.08.14	Ipsen: 2014 Half-Year Results and 2014 Objectives (Businesswire)
06.08.14	Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
01.08.14	Half-Year IPSEN Liquidity Contract Statement Entered into with NATIXIS (Businesswire)
17.07.14	New England Journal of Medicine publishes Ipsen’s Somatuline® CLARINET® Phase III results in patients with metastatic gastroenteropancreatic neuroendocrine tumors (Businesswire)
11.07.14	Ipsen and Galderma become exclusive partners for development and marketing of neurotoxins in the US, Canada, Brazil and Europe1 (Businesswire)
08.07.14	Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
01.07.14	Ipsen submits marketing authorization applications in the US and Europe for Somatuline® (lanreotide) in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

UBS Group	28.46	2.63 %	K V
Swiss Life Hldg	712.60	1.86 %	K V
Part Grp Hldg	1’245.50	1.26 %	K V
Zurich Insur Gr	545.00	1.15 %	K V
Swiss Re	132.70	1.14 %	K V
Givaudan	3’945.00	-0.53 %	K V
Geberit	511.20	-0.66 %	K V
Alcon	76.38	-0.68 %	K V
Sika	212.90	-1.34 %	K V
CieFinRichemont	134.25	-2.65 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Ipsen

Aktien Top/Flop

Meistgelesene Nachrichten